
    
      This is a phase 1A/1B study. Phase 1A is designed to determine the maximal tolerated dose
      (MTD) and toxicity of ridaforolimus in combination with paclitaxel and carboplatin in
      patients with advanced or recurrent solid tumors. The MTD determined in this study will be
      the recommended dose to study in the phase 1B or in future phase 2 trials.
    
  